.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its top biopharma choice for 2025 and rated yet another 9 labels in the area as overweight. The financial investment banking company stated in a keep in mind that it continues to think “diabesity is actually readied to end up being.